Ceftriaxone and the cephalosporin antibiotics explained

Cephalosporins are one of the largest families of antibiotics in clinical use. They are closely related to the penicillins: both are beta-lactam antibiotics, meaning they share a four-membered chemical ring (the beta-lactam ring) that disrupts bacterial cell wall synthesis. Ceftriaxone, a third-generation cephalosporin, is among the best-known members of this family and a mainstay of hospital medicine worldwide. It appears on the WHO Essential Medicines List and is registered for use in South Africa by SAHPRA, the South African Health Products Regulatory Authority. This article explains how cephalosporins are organised, what makes ceftriaxone distinctive, and where these medicines fit in global efforts to curb antimicrobial resistance.

The cephalosporin generations explained

Cephalosporins are commonly grouped into "generations" — a teaching device that reflects how each successive wave of drugs broadened the range of bacteria the class can target. The generation system is not a strict scientific classification, but it is widely used in clinical education and reference materials.

First-generation cephalosporins, such as cephalexin (taken by mouth) and cefazolin (given by injection), are strongest against Gram-positive bacteria — a group that includes streptococci and staphylococci. (Gram staining, named after the Danish bacteriologist Hans Christian Gram, is a laboratory method that sorts bacteria into two broad categories based on their cell wall structure.) Their activity against Gram-negative bacteria is limited. Second-generation agents, such as cefuroxime, modestly expand coverage to certain Gram-negative organisms while retaining useful Gram-positive activity.

Third-generation cephalosporins — including ceftriaxone, cefotaxime, and ceftazidime — extend coverage significantly further against Gram-negative bacteria. Several third-generation agents also reach therapeutic levels in cerebrospinal fluid, which makes them relevant to the treatment of bacterial meningitis. Ceftriaxone additionally has a long half-life — the time it takes for the concentration of a drug in the body to fall by half — which allows for less frequent dosing compared with many other injectable antibiotics. Fourth-generation cephalosporins, such as cefepime, offer broader Gram-negative coverage and greater stability against beta-lactamases — enzymes produced by bacteria that break down beta-lactam antibiotics, conferring resistance. The so-called fifth generation, represented by ceftaroline, adds activity against methicillin-resistant Staphylococcus aureus (MRSA), a pathogen for which most older cephalosporins are not effective. Not all sources agree on the exact boundaries between generations, and newer agents sometimes blur the scheme.

Why ceftriaxone is a hospital staple

Ceftriaxone is administered by intravenous or intramuscular injection — it is not available as an oral tablet — and this alone tends to restrict its use to hospital and other supervised settings. Its broad spectrum of activity, long half-life, and generally favourable safety profile have made it one of the most commonly used injectable antibiotics globally. In many hospitals it is used for a range of serious infections, including certain pneumonias, intra-abdominal infections, urinary tract infections, and sexually transmitted infections.

A notable incompatibility is that ceftriaxone can form an insoluble precipitate with calcium when the two are delivered through the same intravenous line — a fact noted on product labelling and in reference texts. Ceftriaxone is also a good example of a medicine whose patent has long expired: it is widely available as a lower-cost generic, which has contributed to its prominence in public-health programmes and procurement systems, including South Africa's Single Exit Price framework for medicines.

The WHO AWaRe classification

In 2017, the WHO introduced the AWaRe (Access, Watch, Reserve) classification as part of its response to antimicrobial resistance. AWaRe sorts antibiotics into three groups to help guide stewardship and promote appropriate use. The "Access" group includes narrow-spectrum, first-choice antibiotics recommended for common infections that carry a lower risk of driving resistance. The "Watch" group includes antibiotics that have a higher potential to select for resistant organisms; these are generally recommended only as targeted choices for specific, more serious infections. The "Reserve" group contains last-resort agents to be used when other options have failed.

Ceftriaxone sits in the Watch group. This means that, although it is an essential and widely used medicine, WHO guidance encourages its targeted use rather than routine or broad empirical use, in order to preserve its effectiveness. The AWaRe classification is increasingly referenced by national medicines formularies, hospital drug and therapeutics committees, and global health bodies as a tool to slow the emergence of resistance. In South Africa, SAHPRA-registered ceftriaxone products can be searched on HealthSA, and the broader stewardship principles behind AWaRe echo guidance issued by South Africa's National Department of Health.

Cross-reactivity with penicillin allergy

Because cephalosporins share the beta-lactam ring with penicillins, questions of cross-reactivity — whether a person allergic to penicillin will also react to a cephalosporin — are clinically important. Older literature sometimes cited cross-reactivity rates as high as 10 per cent, but more recent reviews suggest the true figure is substantially lower, particularly with later-generation cephalosporins. The nature and severity of the original penicillin reaction also matters: a history of severe, immediate hypersensitivity warrants greater caution than a mild, delayed rash.

Determining whether a cephalosporin is appropriate for a patient with a penicillin allergy is a clinical decision that depends on individual circumstances and local guidelines. Understanding the structural relationship between these antibiotic families, however, helps explain why the question arises in the first place.